NCT02121756View on ClinicalTrials.gov

Dipyridamole for Immune Activation in HIV

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

November 30, 2017

Conditions
HIV Infection
Interventions
DRUG

Dipyridamole

Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24

DRUG

Placebo, then Dipyridamole

Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24

Trial Locations (1)

15213

Pitt Treatment Evaluation Unit / University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Sharon Riddler

OTHER

NCT02121756 - Dipyridamole for Immune Activation in HIV | Biotech Hunter | Biotech Hunter